Activation of AMPK has up-regulated SLC7A2 expression and enhanced the sensitivity of NSCLC cells to anti-tumor drugs, which could be attributed to E2F1’s regulation. The gene discussed is SLC7A2; the disease is non-small cell lung carcinoma.